Patents by Inventor Alvin Ibarra

Alvin Ibarra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220211774
    Abstract: The invention relates to a bacterium of the species Lacticaseibacillus paracasei (formerly known as Lacticaseibacillus paracasei) and compositions comprising a bacterium of the species Lacticaseibacillus paracasei for use in alleviating the psychological and/or physiological response to psychosocial and/or psychological stress and promoting mental and overall well-being, in a mammal. The invention further relates to bacterium of the species Lacticaseibacillus paracasei and compositions comprising a bacterium of the species Lacticaseibacillus paracasei for use in preventing and/or treating a symptom affecting mental health and promoting mental and overall well-being, in a mammal. The invention further relates to methods and uses of said bacterium and/or compositions.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 7, 2022
    Inventors: Elaine PATTERSON, Sixto Alvin IBARRA, Juliane HELLHAMMER, Emilia ELLSIEPEN
  • Patent number: 10092613
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 9, 2018
    Assignee: NATUREX, S.A.
    Inventors: Alvin Ibarra, Marc Roller, Jacques Dikansky
  • Patent number: 9956241
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 1, 2018
    Assignee: Naturex, S.A.
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Publication number: 20160287655
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: June 6, 2016
    Publication date: October 6, 2016
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
  • Patent number: 9358264
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: June 7, 2016
    Assignee: NATUREX, S.A.
    Inventors: Alvin Ibarra, Marc Roller, Jacques DiKansky
  • Publication number: 20160015766
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: March 25, 2011
    Publication date: January 21, 2016
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
  • Publication number: 20150306119
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Application
    Filed: February 27, 2015
    Publication date: October 29, 2015
    Applicant: NATUREX, S.A.
    Inventors: Andrew SCHOLEY, Alvin IBARRA, Kan HE, Marc ROLLER, Jacques DIKANSKY
  • Patent number: 9011936
    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 21, 2015
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques DiKansky
  • Patent number: 8980342
    Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: March 17, 2015
    Assignee: Naturex, S.A.
    Inventors: Benoit Lemaire, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques DiKansky
  • Publication number: 20150072042
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: March 25, 2011
    Publication date: March 12, 2015
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DiKANSKY
  • Patent number: 8968800
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: March 3, 2015
    Assignee: Naturex, S.A.
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Patent number: 8293292
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: October 23, 2012
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques DiKansky, Alvin Ibarra
  • Patent number: 8142826
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl) oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: March 27, 2012
    Assignee: Naturex, Inc.
    Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques Dikansky, Alvin Ibarra
  • Publication number: 20120058210
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl) 2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Application
    Filed: November 10, 2011
    Publication date: March 8, 2012
    Inventors: KAN HE, Marc ROLLER, Antoine BILY, Naisheng BAI, Jacques DIKANSKY, Alvin IBARRA
  • Publication number: 20120046239
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Application
    Filed: November 3, 2011
    Publication date: February 23, 2012
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Publication number: 20110223281
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorgenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: March 25, 2011
    Publication date: September 15, 2011
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DiKANSKY
  • Publication number: 20110091580
    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
    Type: Application
    Filed: October 16, 2009
    Publication date: April 21, 2011
    Inventors: KAN HE, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques Dikansky
  • Publication number: 20100278944
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Application
    Filed: May 4, 2009
    Publication date: November 4, 2010
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Publication number: 20100112098
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 5-caffeoylquinic acid (5-CQA) and total chlorogenic acids (tCGA) (5-CQA/tCGA) of between about 0.2 and 0.3. More preferably, the concentration of tCGA is greater than about 45% and the concentration of 5-CQA is less than about 10%. A preferred method of administration consists of administering between about 200 mg and about 1,000 mg per day, more preferably administering about 400 mg per day.
    Type: Application
    Filed: October 31, 2008
    Publication date: May 6, 2010
    Inventors: Benoit Lemaire, Sophie Lafay, Karine Nardon, Alvin Ibarra, Marc Roller, Jacques Dikansky
  • Publication number: 20100047372
    Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 25, 2010
    Inventors: Benoit LEMAIRE, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques Dikansky